Search clinical trials for: Desvenlafaxine succinate sustained release 25 mg

Total 103 results

Pfizer

Completed

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Major Depressive Disorder

Canada, United States, Colombia, Croatia, Estonia, Finland, Poland, France, Slovakia, Chile, Latvia, Lithuania, Romania, South Africa
Pfizer

Completed

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Jiangsu Province Nanjing Brain Hospital

Recruiting

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Anhedonia

China
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile, Mexico
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Vasomotor Symptoms
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Menopause | Vasomotor System

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Depressive Disorder, Major
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

Depressive Disorder, Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Pfizer

Completed

Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)

Depression - Major Depressive Disorder

Belgium
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder

Major Depressive Disorder

China
Pfizer

Completed

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Vasomotor Symptoms

Canada, United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

Fibromyalgia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Depressive Disorder, Major

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Depressive Disorder, Major

Finland, France, South Africa, Estonia, Croatia, Lithuania, Latvia, Slovakia, Poland, Romania
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Mexico
Pfizer

Completed

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

Major Depressive Disorder

United States
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Pfizer

Completed

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Pharmacokinetics

United States
LG Chem

Unknown

Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions

Type2 Diabetes
XenoPort, Inc.

Completed

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Muscle Spasticity

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers

Healthy
Pfizer

Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Pharmacokinetics | Cytochrome P-450 CYP2D6 | CYP3A4 Protein, Human

United States
LG Life Sciences

Completed

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

Type 2 Diabetes

Korea, Republic of
Saniona

Completed

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

Phase 1

Germany
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia

Fibromyalgia

United States
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Prostate Cancer

China
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

Healthy

United States
Luye Pharma Group Ltd.

Not yet recruiting

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Prostate Cancer

China
Luye Pharma Group Ltd.

Completed

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Breast Cancer

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway

Diabetic Neuropathies | Vasomotor Symptoms | Fibromyalgia | Depressive Disorder, Major
Cosmo Technologies Ltd
Cross S.A.

Completed

Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX (CRO-11-108)

Colon Staining in Preparation for Colonoscopy
Cancer Research Antwerp
Bayer; Veracyte, Inc.

Recruiting

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER)

Prostate Cancer

Belgium
Joint Stock Company "Farmak"

Completed

Fasting Bioequivalence Study of 2 Metformin 500 mg Prolonged Release Tablets in 44 Healthy Male and Female Volunteers

Pharmacokinetics

Czechia
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
University Hospital, Toulouse

Completed

Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2 (CYTOPRO)

Delivery Uterine

France
Hopital Lariboisière

Unknown

Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects (OBEMO2)

Bypass Complications

France

3

Subscribe